Company / Capital Expenditures
Mineralys Therapeutics, Inc. Capital Expenditures History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$96.0K
FY2024
5-year range
$0 / $96.0K
FY2023-FY2024
Trend
-
vs FY2023
Sector context
#169 of 194
Health Care
What the data says
Mineralys Therapeutics, Inc.'s capital expenditures of $96,000 is lower than 87% of companies in the Health Care sector (FY2024).
Based on SEC 10-K filings.
$96,000 in FY2024.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 13% in Health CareTop 87% of 194This company $96.0K Sector average $117.5M
▼
-99.9% below sector average
Key checks
Key Insights
- Ranks #169 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.25 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $96.0K | - |
| FY2023 | $0 | - |
| FY2022 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026